← All trials
NCT04974073
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2017
- Primary completion
- Aug 22, 2017
- Completion date
- Nov 18, 2019
- First posted
- Jul 23, 2021
- Last posted
- Aug 16, 2021
- Enrollment
- 39
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Medical UniversityLead sponsor
- China Medical UniversitySponsor investigator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.